These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 23129424)

  • 21. Plasma chromogranin A: clinical implications in patients with castrate resistant prostate cancer receiving docetaxel chemotherapy.
    Sarkar D; Singh SK; Mandal AK; Agarwal MM; Mete UK; Kumar S; Mavuduru RS; Prasad R
    Cancer Biomark; 2010-2011; 8(2):81-7. PubMed ID: 21896995
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kinetics of neuroendocrine differentiation in an androgen-dependent human prostate xenograft model.
    Jongsma J; Oomen MH; Noordzij MA; Van Weerden WM; Martens GJ; van der Kwast TH; Schröder FH; van Steenbrugge GJ
    Am J Pathol; 1999 Feb; 154(2):543-51. PubMed ID: 10027412
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuroendocrine differentiation in stage D2 prostate cancers.
    Kamiya N; Suzuki H; Kawamura K; Imamoto T; Naya Y; Tochigi N; Kakuta Y; Yamaguchi K; Ishikura H; Ichikawa T
    Int J Urol; 2008 May; 15(5):423-8. PubMed ID: 18452460
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin.
    Xing N; Qian J; Bostwick D; Bergstralh E; Young CY
    Prostate; 2001 Jun; 48(1):7-15. PubMed ID: 11391682
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage I nonsmall cell lung carcinoma.
    Pelosi G; Pasini F; Sonzogni A; Maffini F; Maisonneuve P; Iannucci A; Terzi A; De Manzoni G; Bresaola E; Viale G
    Cancer; 2003 May; 97(10):2487-97. PubMed ID: 12733148
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tissue Chromogranin A Expression during Prostate Cancer Progression: Prediction of Chemosensitivity.
    Mitsui Y; Arichi N; Hiraki M; Harada Y; Yasumoto H; Shiina H
    Urol J; 2015 Jul; 12(3):2165-72. PubMed ID: 26135933
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuroendocrine differentiation in castration resistant prostate cancer. Nuclear medicine radiopharmaceuticals and imaging techniques: A narrative review.
    Usmani S; Orevi M; Stefanelli A; Zaniboni A; Gofrit ON; Bnà C; Illuminati S; Lojacono G; Noventa S; Savelli G
    Crit Rev Oncol Hematol; 2019 Jun; 138():29-37. PubMed ID: 31092382
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Different profiles of neuroendocrine cell differentiation evolve in the PC-310 human prostate cancer model during long-term androgen deprivation.
    Jongsma J; Oomen MH; Noordzij MA; Van Weerden WM; Martens GJ; van der Kwast TH; Schröder FH; van Steenbrugge GJ
    Prostate; 2002 Mar; 50(4):203-15. PubMed ID: 11870798
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer.
    Locke JA; Guns ES; Lubik AA; Adomat HH; Hendy SC; Wood CA; Ettinger SL; Gleave ME; Nelson CC
    Cancer Res; 2008 Aug; 68(15):6407-15. PubMed ID: 18676866
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Skewing towards neuroendocrine phenotype in high grade or high stage androgen-responsive primary prostate cancer.
    Puccetti L; Supuran CT; Fasolo PP; Conti E; Sebastiani G; Lacquaniti S; Mandras R; Milazzo MG; Dogliani N; De Giuli P; Fasolis G
    Eur Urol; 2005 Aug; 48(2):215-21; Discussion 221-3. PubMed ID: 15992991
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The neuroendocrine phenotype in prostate cancer: basic and clinical aspects.
    Mosca A; Berruti A; Russo L; Torta M; Dogliotti L
    J Endocrinol Invest; 2005; 28(11 Suppl International):141-5. PubMed ID: 16625864
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of neuroendocrine differentiation with neoadjuvant hormone therapy effects in prostatic cancer.
    Tokunaga M; Yasuda M; Osamura RY; Itoh J; Mukai M; Shima M; Usui Y; Masuda A; Miyakita H; Terachi T
    Oncol Rep; 2005 Jun; 13(6):1081-7. PubMed ID: 15870925
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic significance of neuroendocrine differentiation in patients with Gleason score 8-10 prostate cancer treated with primary radiotherapy.
    Krauss DJ; Hayek S; Amin M; Ye H; Kestin LL; Zadora S; Vicini FA; Cotant M; Brabbins DS; Ghilezan MI; Gustafson GS; Martinez AA
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e119-25. PubMed ID: 21596486
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Analysis of clinicopathological features of intestinal neuroendocrine neoplasms].
    Gao W; Liu SM; Lu HZ; Liang J; Yuan YL; Liu XY
    Zhonghua Zhong Liu Za Zhi; 2012 Jun; 34(6):450-6. PubMed ID: 22967448
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The prognostic significance of loss of the androgen receptor and neuroendocrine differentiation in prostate biopsy specimens among castration-resistant prostate cancer patients.
    Komiya A; Yasuda K; Watanabe A; Fujiuchi Y; Tsuzuki T; Fuse H
    Mol Clin Oncol; 2013 Mar; 1(2):257-262. PubMed ID: 24649157
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An immunohistochemical study of chromogranin A and human epidermal growth factor-2 expression using initial prostate biopsy specimens from patients with bone metastatic prostate cancer.
    Yamada Y; Nakamura K; Aoki S; Taki T; Naruse K; Matsubara H; Tobiume M; Zennami K; Katsuda R; Honda N
    BJU Int; 2007 Jan; 99(1):189-95. PubMed ID: 17034504
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
    Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
    Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of neuroendocrine differentiation markers in lethal metastatic castration-resistant prostate cancer.
    Sainio M; Visakorpi T; Tolonen T; Ilvesaro J; Bova GS
    Pathol Res Pract; 2018 Jun; 214(6):848-856. PubMed ID: 29728311
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Large-cell neuroendocrine carcinoma of prostate. Case report.
    Moratalla Charcos LM; Pastor Navarro T; Cortes Vizcaino V; Osca Garcia JM; Gil Salom M
    Arch Esp Urol; 2013 May; 66(4):368-71. PubMed ID: 23676541
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nuclear androgen receptor staining in bone metastases is related to a poor outcome in prostate cancer patients.
    Crnalic S; Hörnberg E; Wikström P; Lerner UH; Tieva A; Svensson O; Widmark A; Bergh A
    Endocr Relat Cancer; 2010 Dec; 17(4):885-95. PubMed ID: 20688881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.